Spirepoint Private Client LLC Buys 668 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)
by Jessica Moore · The Cerbat GemSpirepoint Private Client LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 6.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,211 shares of the medical research company’s stock after purchasing an additional 668 shares during the quarter. Spirepoint Private Client LLC’s holdings in Thermo Fisher Scientific were worth $5,579,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently modified their holdings of the company. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $25,000. Pillar Financial Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Noble Wealth Management PBC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $35,000. Finally, Cassady Schiller Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 89.2% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 33 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.
Thermo Fisher Scientific Price Performance
TMO opened at $400.26 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The stock has a market capitalization of $151.09 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.78. The stock’s 50 day moving average price is $411.66 and its 200-day moving average price is $486.42.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the previous year, the firm earned $5.11 earnings per share. The business’s revenue was up .2% compared to the same quarter last year. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.
Insider Activity at Thermo Fisher Scientific
In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the company. Barclays decreased their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Royal Bank Of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Finally, Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $605.30.
Check Out Our Latest Stock Analysis on TMO
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Dividend Capture Strategy: What You Need to Know
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- How to Plot Fibonacci Price Inflection Levels
- D-Wave Goes International With South Korea Partnership
- The Risks of Owning Bonds
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).